INS and Hypoglycemia: Consistently, a combined therapy of long-acting GLP-1 RAs and basal insulin may significantly lower HbA1c levels and reduce the risk of hypoglycaemia in patients without HF, whereas SGLT-2Is may significantly decrease HF incidence and hospitalization for HF.